跳至主要内容
临床试验/JPRN-UMIN000003197
JPRN-UMIN000003197已完成3 期

A Phase III Study Comparing Methotrexate, Adrimycin and Cisplatin (MAP) with MAP + Ifosfamide (MAP + IF) for the Treatment of Osteosarcoma (JCOG0905/OS-MAP + IF-P3) - A Phase III Study Comparing Methotrexate, Adrimycin and Cisplatin (MAP) with MAP + Ifosfamide (MAP + IF) for the Treatment of Osteosarcoma (JCOG0905/OS-MAP + IF-P3)

Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 250 人开始时间: 2010年2月16日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
250

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 50years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Uncontrollable diabetes mellitus. 2) Uncontrollable hypertension. 3) History of myocardial infarction or attack of unstable angina pectoris. 4) Artificial pacemaker. 5) Active bacterial or fungous infection. 6) Fever over 38 degrees centigrade. 7) Simultaneous or metachronous (within the past 5 years) double cancers. 8) Women during pregnancy or breast-feeding. 9) Women within 28 days after delivery or women 29 days or more after delivery without uterine subinvolution confirmed by an obstetrician. 10) Psychosis. 11) Systemic steroids medication. 12) Positive for HBs antigen, HBc antibody, or HBs antibody.

研究者

发起方
Japan Clinical Oncology Group(JCOG)

相似试验